Myelodysplastic Syndromes: Impact of Recently Analyzed Variables for Modifying Current Classification Methods

Kao, Jelena M.; Greenberg, Peter L.

doi:10.3816/clk.2007.n.005

Cited by 2 publications

(1 citation statement)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PROGNOSIS Searching for prognostic variables for reliable stratifications of MDS patients, predictions of mortality and blastic transformation has started approx. in 1980 (22). Several prognostic scoring systems have been proposed, among them the most important and widely used are IPSS and IPSS-R. Clinical course of the disease is variable, but without therapy and often also despite treatement it is fatal (23).…”

Section: Pathogenesismentioning

confidence: 99%

The Differencies in Adult and Pediatric Myelodysplastic Syndrome: A Review

Vasekova

2016

Acta Medica Martiniana

View full text Add to dashboard Cite

Myelodysplastic syndrome (MDS) represent very heterogenous group of clonal stem cell bone marrow disorders with ineffective haematopoesis leading to cytopenias in peripheral blood and increased risk of blastic transformation and evolution of acute myeloid leukemia. MDS is a disease of older age mostly, in children it seems to be very rare. There are several significant morphological, cytogenetic and prognostic differencies of the disease in adults and in children. Adult MDS patients most commonly manifest with symptoms of anemia, bleeding and infection are uncommon. In childhood, MDS manifests predominantly by neutropenia and thrombocytopenia. In addition, some pediatric MDS patients present also with constitutional disease’s signs and symptoms. Early and correct diagnosis in both age groups is essential for the choice of appropriate therapy and also for next life of patients. However, the diagnosis of MDS is challenging, complex and requiring close correlation of clinical symptoms, laboratory parameters and standardized examination of BM biopsies. The authors present an overview focused on biology of MDS in adults and children, on the differences in the incidence, clinical presentation and treatment. They summarize the possibilities and limits of histopathological diagnosis and differential diagnosis of the disease in different age groups. A major problem in the morphological diagnosis of MDS remains the determination, whether the myelodysplasia is due to clonal disorder. It might result also from some other factors, as significant dysplasia can also occur in reactive conditions, and vice versa, only discrete dysplasia is sometimes observed in MDS patients. Although histomorphological and immunohistochemical analysis of BM biopsy is invasive and time-consuming examination, it has its value in the diagnosis, differential diagnosis and evaluation of therapeutic effect.

show abstract

Section: Pathogenesismentioning

confidence: 99%

The Differencies in Adult and Pediatric Myelodysplastic Syndrome: A Review

Vasekova

2016

Acta Medica Martiniana

View full text Add to dashboard Cite

show abstract

Current therapeutic approaches for patients with myelodysplastic syndromes

Greenberg

2010

Br J Haematol

Self Cite

View full text Add to dashboard Cite

SummaryThe myelodysplastic syndromes (MDS) are a heterogeneous spectrum of disorders requiring selective therapy based on patients' specific clinical features, predominantly their prognostic subgroups, age and performance status. Guidelines for management of patients with MDS have been generated by a number of national panels. This review focuses on evidencebased data supporting therapeutic approaches, which have also been recommended by the US National Comprehensive Cancer Network MDS Panel, with discussion of accessibility of recommended drugs in the US and in other countries. For lower risk disease (International Prognostic Scoring System Low and Intermediate-1) therapy is aimed at haematological improvement whereas for higher risk disease (Intermediate-2 and High) treatment focuses on altering disease natural history. Recent information regarding additional clinical and biological features has provided useful parameters for assessing disease prognosis that aid risk-based management decisions. The rationale for use of low versus high intensity therapies with these agents, including allogeneic haematopoietic stem cell transplantation, is discussed in detail.

show abstract

Myelodysplastic Syndromes: Impact of Recently Analyzed Variables for Modifying Current Classification Methods

Cited by 2 publications

References 90 publications

The Differencies in Adult and Pediatric Myelodysplastic Syndrome: A Review

The Differencies in Adult and Pediatric Myelodysplastic Syndrome: A Review

Current therapeutic approaches for patients with myelodysplastic syndromes

Contact Info

Product

Resources

About